Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...

Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...

The study met its primary endpoint in enhancing event-free survival over 12 months when compared to historical control groups ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

Financially risky OS Therapies has potential with mid-stage immunotherapy for osteosarcoma, but faces funding challenges and ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.

Alejandra Carvajal, the Senior Vice President and Chief Legal Officer of Mersana Therapeutics, Inc. (NASDAQ:MRSN), recently ...

Breast Cancer Diagnostic And Drug Technologies Market Breast cancer is the most common cancer among women worldwide, with an estimated 2.3 ...

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo and Roche.

Breast cancer classed as HER2-positive – defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease.

Novotech, the leading global full-service clinical Contract Research Organization (CRO), has released a comprehensive report analyzing the global clinical trial and drug development landscape for ...